ZA201702813B - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Info

Publication number
ZA201702813B
ZA201702813B ZA2017/02813A ZA201702813A ZA201702813B ZA 201702813 B ZA201702813 B ZA 201702813B ZA 2017/02813 A ZA2017/02813 A ZA 2017/02813A ZA 201702813 A ZA201702813 A ZA 201702813A ZA 201702813 B ZA201702813 B ZA 201702813B
Authority
ZA
South Africa
Prior art keywords
glucocorticoid
receptor antagonists
liver disease
fatty liver
disease treatment
Prior art date
Application number
ZA2017/02813A
Other languages
English (en)
Inventor
Joseph K Belanoff
Hazel Hunt
Onno C Meijer
Den Heuvel Jose Van
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of ZA201702813B publication Critical patent/ZA201702813B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/02813A 2014-10-15 2017-04-21 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists ZA201702813B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
ZA201702813B true ZA201702813B (en) 2019-05-29

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/02813A ZA201702813B (en) 2014-10-15 2017-04-21 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3206692T (pt) 2014-10-15 2024-04-30 Corcept Therapeutics Inc Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides
JP7196201B2 (ja) * 2018-06-04 2022-12-26 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
KR20210153056A (ko) 2019-03-18 2021-12-16 리네트 케이. 니만 인슐린 감수성 개선 방법
AU2021266739B2 (en) * 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3182272A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
KR20230124020A (ko) 2020-12-21 2023-08-24 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 시클로헥실 글루코코르티코이드 수용체 조절제의제조 방법
AU2022271209A1 (en) * 2021-05-05 2023-11-09 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
US7745657B2 (en) 2005-05-18 2010-06-29 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
MX2009011062A (es) 2007-04-13 2009-10-29 Schering Corp Derivados de pirimidindiona y sus metodos de uso.
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
JP6039587B2 (ja) 2011-03-18 2016-12-07 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子
PT3206692T (pt) 2014-10-15 2024-04-30 Corcept Therapeutics Inc Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides

Also Published As

Publication number Publication date
UA123537C2 (uk) 2021-04-21
NZ731060A (en) 2023-07-28
KR102435956B1 (ko) 2022-08-23
EP3206692A1 (en) 2017-08-23
CN107106562B (zh) 2020-08-18
MX2017004943A (es) 2017-07-19
RU2718921C2 (ru) 2020-04-15
DK3206692T3 (da) 2024-04-29
ES2978871T3 (es) 2024-09-23
RU2017114596A3 (OSRAM) 2019-05-08
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
US10238659B2 (en) 2019-03-26
JP6761410B2 (ja) 2020-09-23
JP2017531013A (ja) 2017-10-19
AU2015333645A1 (en) 2017-05-04
US10881660B2 (en) 2021-01-05
EP3206692B1 (en) 2024-04-03
EP4353310A3 (en) 2024-06-19
FI3206692T3 (fi) 2024-05-06
BR112017007860B1 (pt) 2023-03-07
IL251729A0 (en) 2017-06-29
US20230218621A1 (en) 2023-07-13
CA2964625C (en) 2023-03-07
US20160106749A1 (en) 2016-04-21
US20190151318A1 (en) 2019-05-23
AU2015333645B2 (en) 2020-01-30
KR20170066646A (ko) 2017-06-14
PH12017500710A1 (en) 2017-10-09
RU2017114596A (ru) 2018-11-15
PL3206692T3 (pl) 2024-07-22
PH12017500710B1 (en) 2024-01-17
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
SG11201703024VA (en) 2017-05-30
US11590135B2 (en) 2023-02-28
EP3206692A4 (en) 2018-05-30
CA2964625A1 (en) 2016-04-21
CN111557942A (zh) 2020-08-21
US20210085682A1 (en) 2021-03-25
IL251729B (en) 2020-03-31
WO2016061195A1 (en) 2016-04-21
US12226417B2 (en) 2025-02-18
BR112017007860A2 (pt) 2018-01-16
EP4353310A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
ZA201702813B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
IL247713A0 (en) Indazole 3-carboxyamides converted at the 5-position, their preparation and their use
SG11201609645YA (en) Device for connecting the structural elements of ribs and reticular structures
AU201710083S (en) Bowl and Covered Bowl
GB201404470D0 (en) Therapeutic methods and materials
AU357565S (en) Mixing bowls
IL246779A0 (en) Methods for the treatment and prevention of kidney disorders and fatty liver disorders
ZA201706671B (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
SG11201608217PA (en) Fatty acid composition and use thereof
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates
IL249203A0 (en) Androgen receptor modulators and methods of using them
GB201417022D0 (en) Mixing bowl
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
IL247828A0 (en) Progesterone compounds
IL246944A0 (en) A process for the preparation of abiraterone acetate and its intermediates
GB201612052D0 (en) Animal claw shearing apparatuses and methods of using the same
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201520661D0 (en) Mixing bowl
GB201411741D0 (en) Mixing bowl stand
GB201402210D0 (en) Mixing bowl
GB201419977D0 (en) Dynamic mixer and mixing
GB201402629D0 (en) Improved mixer and associated methods
GB201419559D0 (en) Therapeutic compositions and methods